Symbiotec Pharmalab IPO: Should you subscribe?

Abstract: Symbiotec Pharmalab dominates a distinct segment world market, however its subsequent part of development is dependent upon companies which are nonetheless discovering their ft. We study whether or not its strengths justify the expectations constructed into the IPO value. 

Symbiotec Pharmalab, a pharmaceutical firm that manufactures lively substances (APIs) utilized in medicines, opened its IPO (initial public offering) right this moment (August 24, 2026). Its IPO, valued at Rs 1,757 crore, is sort of fully a proposal on the market, with simply Rs 150 crore comprising a contemporary concern. 

At the moment, the corporate leads its world market by a large margin and earns wholesome working margins. However its latest vegetation are but to provide commercially, loss-making subsidiaries are draining the mother or father, and revenue has barely moved in two years. The IPO costs the corporate at about 58 occasions earnings earlier than any of that’s fastened.

Right here, we have a look at Symbiotec’s financials, enterprise and observe report to evaluate whether or not the IPO is price subscribing to. 

In regards to the firm

Symbiotec makes the lively ingredient (APIs) that goes inside a medication. Its prospects are drug firms, which take that ingredient and switch it into inhalers, lotions, injections and tablets.

Almost the whole lot it makes belongs to 1 household: corticosteroids, medication that scale back swelling and irritation within the physique, used for bronchial asthma, pores and skin rashes or arthritis ache. As well as, Symbiotec makes steroidal hormones, which go into hormone alternative remedy and a few most cancers therapies. On this slim discipline, it’s the world’s largest provider, accounting for 38.2 per cent of worldwide corticosteroid quantity and 23.8 per cent of steroidal hormone quantity. In all, Symbiotec sells greater than 60 substances to over 200 prospects.

The income combine is lopsided. Ingredient gross sales introduced in 96 per cent of the whole in FY26. Prepared-to-use injections, offered for the primary time final yr, and contract manufacturing for different drug companies made up the remaining. Exports account for 67 per cent of income, up from 55 per cent a yr earlier. America drove that bounce, with gross sales rising from Rs 30 crore to Rs 114 crore. Indian gross sales fell from Rs 337 crore to Rs 287 crore.

What the enterprise will get proper 

#1 Lengthy-standing clientele

Switching suppliers is expensive in steroid and hormone APIs, the place manufacturing can contain as much as 400 validated synthesis steps. A change can even require contemporary testing and regulatory filings, making prospects reluctant to modify. Symbiotec’s prime 5 and prime 10 prospects have stayed for greater than 10 years on common, whereas prospects with relationships of over seven years contributed 69.5 per cent of FY26 income. 

#2 Shifting up the worth chain 

Symbiotec is steadily transferring past fundamental APIs into extra complicated merchandise. Its new injectable enterprise generated Rs 33 crore in FY26, up from nil a yr earlier, whereas fermentation expands its capabilities into insulin, biologics and contract manufacturing. The primary two injectable merchandise are anticipated to launch in FY27 and may command a 20 to 50 per cent premium over typical vials. With 5 extra injectables in improvement, this might grow to be a bigger income stream. 

#3 Making extra inputs in-house 

Symbiotec makes key beginning supplies in-house for merchandise accounting for greater than 80 per cent of its income. This backward integration reduces its dependence on exterior suppliers and provides it higher management over prices and provide. It exhibits within the import invoice: purchases from China fell from 53 per cent of whole bills in FY24 to 23.9 per cent in FY26. That additionally helps defend margins in a enterprise the place API costs can face strain. 

What the enterprise will get incorrect

#1 A market with little room to develop 

The 2 households Symbiotec leads are price roughly Rs 6,350 crore worldwide, and the business is estimated to develop at 1-3 per cent a yr to 2030. Symbiotec already holds near two-fifths of one in every of them by quantity. It can’t develop by rising with the market, as a result of the market barely strikes. Each further rupee should come from taking share from a rival. 

#2 New capability is dragging earnings 

Symbiotec has Rs 970 crore tied up in its new injectables and fermentation vegetation, in opposition to a web price of Rs 1,150 crore. Each have been commissioned solely in March 2026 and are nonetheless working pilot batches whereas awaiting approvals. Collectively, the 2 subsidiaries misplaced Rs 28.5 crore in FY26, dragging on earnings till commercialisation picks up. 

What the value is asking

On the higher finish of the value band, Symbiotec Pharmalab is valued at about 58 occasions earnings. That may be a demanding value for a enterprise whose income has grown at 10 per cent yearly over two years, whereas revenue has grown solely 5 per cent. Its dominant place, sticky prospects and backward integration make it troublesome to duplicate, however these benefits haven’t but translated into excessive returns. Return on fairness stood at 11.2 per cent in FY26, down from 14 per cent two years earlier.

The valuation is subsequently asking buyers to look past the present numbers. Symbiotec is constructing a second part of development by means of injectables, fermentation and biologics, which may make its product combine extra beneficial. However these companies are nonetheless scaling and, for now, the brand new vegetation are a drag on earnings. Till these premium merchandise scale up meaningfully, the present value leaves little margin of security.

Additionally learn: How to win the IPO game: IPO handbook